Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8295)
All Articles published online
|
Jul 7, 2010 (publication date) through Feb 8, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143 [PMID: 20593498 DOI: 10.3748/wjg.v16.i25.3133] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i25/3133.htm |
| Number | Citing Articles |
| 1 |
Septiara Putri, Siti Rizny F. Saldi, Levina Chandra Khoe, Ery Setiawan, Amila Megraini, Benjarin Santatiwongchai, Ryan R. Nugraha, Vetty Y. Permanasari, Mardiati Nadjib, Sudigdo Sastroasmoro, Armansyah Armansyah. Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11253-y
|
| 2 |
Tanios Bekaii-Saab, Christina Wu. Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Critical Reviews in Oncology/Hematology 2014; 91(1): 9 doi: 10.1016/j.critrevonc.2014.01.001
|
| 3 |
Jinghui Wang, Li Luo, Dingxue Wang, Bin Guo, Jun Li, Zhu Yang, Dongxin Tang. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta‐analysis. Journal of Cellular Biochemistry 2018; 119(2): 1521 doi: 10.1002/jcb.26312
|
| 4 |
Long Wang, Yi-zhi Chen, Duo Shi, Xue-yin Shi, Zui Zou, Jian-hua Zhao. Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with Cetuximab. Drugs in R&D 2011; 11(4): 317 doi: 10.2165/11598190-000000000-00000
|
| 5 |
CHEN YU, SHEN-LIN LIU, MING-HAO QI, XI ZOU. Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. Molecular Medicine Reports 2014; 9(2): 669 doi: 10.3892/mmr.2013.1830
|
| 6 |
Sara Cignola, Silvia Gonella, Bin Alessandra, Alvisa Palese. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients. European Journal of Oncology Nursing 2016; 20: 133 doi: 10.1016/j.ejon.2015.07.003
|
| 7 |
Marie Westwood, Thea van Asselt, Bram Ramaekers, Penny Whiting, Manuela Joore, Nigel Armstrong, Caro Noake, Janine Ross, Johan Severens, Jos Kleijnen. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment 2014; 18(62): 1 doi: 10.3310/hta18620
|
| 8 |
Hao Zhuang, Zhen-yi Xue, Lu Wang, Xiao-yan Li, Ning Zhang, Rong-xin Zhang. Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer. Clinical Oncology and Cancer Research 2011; 8(4): 207 doi: 10.1007/s11805-011-0582-8
|
| 9 |
Long Wang, Yi-zhi Chen, Duo Shi, Xue-yin Shi, Zui Zou, Jian-hua Zhao. Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with Cetuximab. Drugs in R&D 2011; 11(4): 317 doi: 10.2165/11598190-000000000-00000
|
| 10 |
Linlin Zhang, Li Ma, Qinghua Zhou. Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. International Journal of Colorectal Disease 2011; 26(8): 1025 doi: 10.1007/s00384-011-1197-5
|
| 11 |
Gilles Manceau, Sandrine Imbeaud, Raphaële Thiébaut, François Liébaert, Karine Fontaine, Francis Rousseau, Bérengère Génin, Delphine Le Corre, Audrey Didelot, Marc Vincent, Jean-Baptiste Bachet, Benoist Chibaudel, Olivier Bouché, Bruno Landi, Frédéric Bibeau, Karen Leroy, Frédérique Penault-Llorca, Jean-Luc Van Laethem, Pieter Demetter, Sabine Tejpar, Simona Rossi, Neda Mosakhani, Pia Österlund, Raija Ristamäki, Virinder Sarhadi, Sakari Knuutila, Valérie Boige, Thierry André, Pierre Laurent-Puig. Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. Clinical Cancer Research 2014; 20(12): 3338 doi: 10.1158/1078-0432.CCR-13-2750
|
| 12 |
S. Stintzing, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jäger, T. Heintges, C. Stoll, C. Giessen, D.P. Modest, J. Neumann, A. Jung, T. Kirchner, W. Scheithauer, V. Heinemann. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Annals of Oncology 2012; 23(7): 1693 doi: 10.1093/annonc/mdr571
|
| 13 |
Jose J. G. Marin, Fermin Sanchez de Medina, Beatriz Castaño, Luis Bujanda, Marta R. Romero, Olga Martinez-Augustin, Rosario Del Moral-Avila, Oscar Briz. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews 2012; 44(2): 148 doi: 10.3109/03602532.2011.638303
|
| 14 |
Jean-Baptiste Bachet, Lucie Peuvrel, Claude Bachmeyer, Ziad Reguiai, Pierre A. Gourraud, Olivier Bouché, Marc Ychou, Rene J. Bensadoun, Brigitte Dreno, Thierry André. Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. The Oncologist 2012; 17(4): 555 doi: 10.1634/theoncologist.2011-0365
|
| 15 |
Geoffrey Y. Ku, Benjamin A. Haaland, Gilberto de Lima Lopes. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemotherapy and Pharmacology 2012; 70(2): 231 doi: 10.1007/s00280-012-1898-7
|
| 16 |
Sebastian Stintzing, Christine Kapaun, Rüdiger Paul Laubender, Andreas Jung, Jens Neumann, Dominik Paul Modest, Clemens Giessen, Nicolas Moosmann, Andreas Wollenberg, Thomas Kirchner, Volker Heinemann. Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group. International Journal of Cancer 2013; 132(1): 236 doi: 10.1002/ijc.27654
|
| 17 |
Kenta Baba, Akihiko Oshita, Mohei Kohyama, Satoshi Inoue, Yuta Kuroo, Takuro Yamaguchi, Hiroyuki Nakamura, Yoichi Sugiyama, Tatsuya Tazaki, Masaru Sasaki, Yuji Imamura, Yutaka Daimaru, Hideki Ohdan, Atsushi Nakamitsu. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis. World Journal of Gastroenterology 2015; 21(6): 1982-1988 doi: 10.3748/wjg.v21.i6.1982
|
| 18 |
David L. Chan, Nick Pavlakis, Jeremy Shapiro, Timothy J. Price, Christos S. Karapetis, Niall C. Tebbutt, Eva Segelov, Rafael Rosell. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLOS ONE 2015; 10(8): e0135599 doi: 10.1371/journal.pone.0135599
|
| 19 |
Mei-Ying Liao, Jun-Kai Lai, Mark Yen-Ping Kuo, Ruei-Min Lu, Cheng-Wei Lin, Ping-Chang Cheng, Kang-Hao Liang, Han-Chung Wu. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 2015; 6(28): 24947 doi: 10.18632/oncotarget.4453
|
| 20 |
Ondrej Fiala, Veronika Veskrnova, Renata Chloupkova, Alexandr Poprach, Igor Kiss, Katerina Kopeckova, Ladislav Dusek, Lubomir Slavicek, Milan Kohoutek, Jindrich Finek, Marek Svoboda, Lubos Petruzelka, Ludmila Boubliková, Josef Dvorak, Bohuslav Melichar, Tomas Buchler. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology 2018; 13(6): 735 doi: 10.1007/s11523-018-0597-7
|
| 21 |
Rebecca Y Kim, Hua Xu, Samuel Myllykangas, Hanlee Ji. Genetic-Based Biomarkers and Next-Generation Sequencing: The Future of Personalized Care in Colorectal Cancer. Personalized Medicine 2011; 8(3): 331 doi: 10.2217/pme.11.16
|
| 22 |
Gerald W. Prager, Kira H. Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph C. Zielinski. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer. Cancer Science 2014; 105(8): 996 doi: 10.1111/cas.12451
|
| 23 |
E. J. van Helden, C. W. Menke-van der Houven van Oordt, M. W. Heymans, J. C. F. Ket, R. van den Oord, H. M. W. Verheul. Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer and Metastasis Reviews 2017; 36(2): 395 doi: 10.1007/s10555-017-9668-y
|
| 24 |
Erica L. Bradshaw-Pierce, Todd M. Pitts, Gillian Kulikowski, Heather Selby, Andrea L. Merz, Daniel L. Gustafson, Natalie J. Serkova, S. Gail Eckhardt, Colin D. Weekes, Joseph Alan Bauer. Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer. PLoS ONE 2013; 8(3): e58089 doi: 10.1371/journal.pone.0058089
|
| 25 |
Maen Abdelrahim, Scott Kopetz, David Menter. Targeted Therapy in Translational Cancer Research. 2015; : 193 doi: 10.1002/9781118468678.ch20
|
| 26 |
Dominik Paul Modest, Anke Reinacher-Schick, Sebastian Stintzing, Clemens Giessen, Andrea Tannapfel, Ruediger Paul Laubender, Thomas Brodowicz, Regina Knittelfelder, Damir Vrbanec, Wolff Schmiegel, Volker Heinemann, Christoph C. Zielinski. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer. Anti-Cancer Drugs 2012; 23(6): 666 doi: 10.1097/CAD.0b013e328352ff1d
|
| 27 |
Stavroula Koilakou, Panagiotis Petrou. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Molecular Diagnosis & Therapy 2021; 25(6): 715 doi: 10.1007/s40291-021-00560-4
|
| 28 |
E. Gabriela Chiorean, Andrew Coveler, Jon Grim, William M. Grady. Intestinal Tumorigenesis. 2015; : 391 doi: 10.1007/978-3-319-19986-3_13
|
| 29 |
Yassine Ridouane, Gilberto Lopes, Geoffrey Ku, Hasan Masud, Benjamin Haaland. Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis. Oncotarget 2017; 8(39): 66458 doi: 10.18632/oncotarget.20185
|
| 30 |
Roberto Cirocchi, Stefano Trastulli, Iosief Abraha, Nereo Vettoretto, Carlo Boselli, Alessandro Montedori, Amilcare Parisi, Giuseppe Noya, Cameron Platell. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable Stage IV colorectal cancer. Cochrane Database of Systematic Reviews 2012; doi: 10.1002/14651858.CD008997.pub2
|
| 31 |
B. Schultheis, G. Folprecht, J. Kuhlmann, R. Ehrenberg, U.T. Hacker, C.H. Köhne, M. Kornacker, O. Boix, J. Lettieri, J. Krauss, R. Fischer, S. Hamann, D. Strumberg, K.B. Mross. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals of Oncology 2013; 24(6): 1560 doi: 10.1093/annonc/mdt056
|
| 32 |
Eva Gupta, Napoleon Santos, Yanxia Liu, Pamela Havre, Nam H. Dang, Hendrik Luesch, Long H. Dang. Targeting HIF-1α and HIF-2α to Overcome Treatment Resistance Mediated by Oncogenic KRAS in Colorectal Cancer. Journal of Cancer Therapy 2013; 4(06): 1132 doi: 10.4236/jct.2013.46129
|
| 33 |
Robert M. Sharkey, David M. Goldenberg. Nuclear Medicine Therapy. 2013; : 207 doi: 10.1007/978-1-4614-4021-5_13
|
| 34 |
O. Coutelle, M. Hallek, U. T. Hacker. Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer. memo - Magazine of European Medical Oncology 2011; 4(2): 75 doi: 10.1007/s12254-011-0265-4
|
| 35 |
T. Brodowicz, T.E. Ciuleanu, D. Radosavljevic, E. Shacham-Shmueli, D. Vrbanec, S. Plate, Z. Mrsic-Krmpotic, M. Dank, G. Purkalne, D. Messinger, C.C. Zielinski. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Annals of Oncology 2013; 24(7): 1769 doi: 10.1093/annonc/mdt116
|
| 36 |
Hidehiko Takigawa, Yasuhiko Kitadai, Kei Shinagawa, Ryo Yuge, Yukihito Higashi, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. Cancer Science 2016; 107(5): 601 doi: 10.1111/cas.12907
|
| 37 |
Payam Azadeh, Nafiseh Mortazavi, Arezoo Tahmasebi, Farnaz Hosseini Kamal, Kambiz Novin. Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer. Chemotherapy 2016; 61(1): 51 doi: 10.1159/000440693
|
| 38 |
Julen Fernandez-Plana, Carlos Pericay, Guillermo Quintero, Vicente Alonso, Antonieta Salud, Miguel Mendez, Mercedes Salgado, Eugeni Saigi, Luis Cirera. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-865
|
| 39 |
René Adam, Emir Hoti, Luis César Bredt. Estrategias oncoquirúrgicas en el cáncer hepático metastásico. Cirugía Española 2011; 89(1): 10 doi: 10.1016/j.ciresp.2010.10.007
|
| 40 |
Zhengyun Zou, Li Xie, Jia Wei, Lixia Yu, Xiaoping Qian, Junhao Chen, Tingting Wang, Baorui Liu. Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines. BMC Complementary and Alternative Medicine 2012; 12(1) doi: 10.1186/1472-6882-12-58
|
| 41 |
Autumn J. McRee, Richard M. Goldberg. Optimal Management of Metastatic Colorectal Cancer. Drugs 2011; 71(7): 869 doi: 10.2165/11591770-000000000-00000
|
| 42 |
PENG CHEN, LONG WANG, HAO LI, BING LIU, ZUI ZOU. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncology Letters 2013; 5(6): 1915 doi: 10.3892/ol.2013.1301
|
| 43 |
Claire Jones, Mark A. Taylor, Billy McWilliams. The role of cetuximab as first‐line treatment of colorectal liver metastases. HPB 2013; 15(1): 11 doi: 10.1111/j.1477-2574.2012.00591.x
|
| 44 |
Nobuhisa Matsuhashi, Takao Takahashi, Satoshi Matsui, Toshiyuki Tanahashi, Hisashi Imai, Yoshihiro Tanaka, Kazuya Yamaguchi, Kazuhiro Yoshida. A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. International Journal of Oncology 2018; doi: 10.3892/ijo.2018.4322
|
| 45 |
Bengt Glimelius, Nina Cavalli-Björkman. Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach – present status. Scandinavian Journal of Gastroenterology 2012; 47(3): 296 doi: 10.3109/00365521.2012.640828
|
| 46 |
Amandine Gouverneur, Francesco Salvo, Driss Berdaï, Nicholas Moore, Annie Fourrier-Réglat, Pernelle Noize. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. Journal of Geriatric Oncology 2018; 9(1): 15 doi: 10.1016/j.jgo.2017.08.001
|
| 47 |
Nirit Yarom, Gillian Gresham, Nana Boame, Derek Jonker. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2019; 18(4): e309 doi: 10.1016/j.clcc.2019.05.004
|
| 48 |
Alfredo Carrato, Albert Abad, Bartomeu Massuti, Cristina Grávalos, Pilar Escudero, Federico Longo-Muñoz, José-Luis Manzano, Auxiliadora Gómez, María José Safont, Javier Gallego, Beatriz García-Paredes, Carles Pericay, Rosario Dueñas, Fernando Rivera, Ferrán Losa, Manuel Valladares-Ayerbes, Encarnación González, Enrique Aranda. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). European Journal of Cancer 2017; 81: 191 doi: 10.1016/j.ejca.2017.04.024
|
| 49 |
Sujin Kim, Nayoung Kim, Keunsoo Kang, Wonkyung Kim, Jonghwa Won, Jeonghee Cho. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Cells 2019; 8(8): 878 doi: 10.3390/cells8080878
|
| 50 |
Junya Shirai, Chikara Kunisaki, Ten-i Godai, Kazuteru Watanabe, Takashi Oshima, Norio Yukawa, Shouichi Fujii, Yasushi Rino, Munetaka Masuda. A Case of Locally Advanced Colon Cancer Treated with Resection After CapeOX and Bevacizumab Combination Chemotherapy. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 2012; 37(4): 813 doi: 10.4030/jjcs.37.813
|
| 51 |
Miguel Jhonatan Sotelo Lezama, Javier Sastre Valera, Eduardo Díaz-Rubio García. Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy 2014; 14(3): 387 doi: 10.1517/14712598.2014.883376
|
| 52 |
G. Poston, R. Adam, J. Xu, B. Byrne, R. Esser, H. Malik, H. Wasan, J. Xu. The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. European Journal of Surgical Oncology 2017; 43(11): 2001 doi: 10.1016/j.ejso.2017.07.021
|
| 53 |
Tung Hoang, Dae Kyung Sohn, Byung Chang Kim, Yongjun Cha, Jeongseon Kim. Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.756214
|
| 54 |
Shelby N. Bess, Gage J. Greening, Timothy J. Muldoon. Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. Cytokine & Growth Factor Reviews 2019; 49: 1 doi: 10.1016/j.cytogfr.2019.10.002
|
| 55 |
W. Schmiegel, A. Reinacher-Schick, D. Arnold, S. Kubicka, W. Freier, G. Dietrich, M. Geißler, S. Hegewisch-Becker, A. Tannapfel, M. Pohl, A. Hinke, H.J. Schmoll, U. Graeven. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of Oncology 2013; 24(6): 1580 doi: 10.1093/annonc/mdt028
|
| 56 |
Clemens Giessen, Ruediger Paul Laubender, Donna Pauler Ankerst, Sebastian Stintzing, Dominik Paul Modest, Ulrich Mansmann, Volker Heinemann. Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials. Clinical Cancer Research 2013; 19(1): 225 doi: 10.1158/1078-0432.CCR-12-1515
|
| 57 |
Ann-Lii Cheng, Gerardo Cornelio, Lin Shen, Timothy Price, Tsai-Sheng Yang, Ik Joo Chung, Guang-Hai Dai, Jen-Kou Lin, Atul Sharma, Kun-Huei Yeh, Brigette Ma, Adel Zaatar, Zhongzhen Guan, Nehal Masood, Vichien Srimuninnimit, Thomas Yau, Peter Gibbs, Xiuwen Wang, Dinesh Chandra Doval, Seung-Taek Oh, Byoung Yong Shim, Charity Gorospe, Hwei-Ming Wang, Ekaphop Sirachainan, Andrew Hill, Kwang Wook Suh, Frank Beier, Sudipto Chatterjee, Robert Lim. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer 2017; 16(2): e73 doi: 10.1016/j.clcc.2016.08.005
|
| 58 |
Tung Hoang, Jeongseon Kim. Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers 2020; 12(9): 2663 doi: 10.3390/cancers12092663
|
| 59 |
E Elez, A Hendlisz, T Delaunoit, J Sastre, A Cervantes, R Varea, G Chao, J Wallin, J Tabernero. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. British Journal of Cancer 2016; 114(4): 372 doi: 10.1038/bjc.2015.480
|
| 60 |
Augusta N. Uwah, Joan Ackler, John C. Leighton, Sherry Pomerantz, William Tester. The Effect of Diabetes on Oxaliplatin-Induced Peripheral Neuropathy. Clinical Colorectal Cancer 2012; 11(4): 275 doi: 10.1016/j.clcc.2012.05.002
|
| 61 |
Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, Frederic Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, Fortunato Ciardiello. Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology 2012; 30(23): 2861 doi: 10.1200/JCO.2011.40.9243
|
| 62 |
Anke Reinacher-Schick, Karsten Schulmann, Dominik P Modest, Nina Bruns, Ulrich Graeven, Malgorzata Jaworska, Richard Greil, Rainer Porschen, Dirk Arnold, Wolff Schmiegel, Andrea Tannapfel. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-349
|
| 63 |
D.P. Modest, A. Jung, N. Moosmann, R.P. Laubender, C. Giessen, C. Schulz, M. Haas, J. Neumann, S. Boeck, T. Kirchner, V. Heinemann, S. Stintzing. The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial. International Journal of Cancer 2012; 131(4): 980 doi: 10.1002/ijc.26467
|
| 64 |
Goro Nakayama, Ayako Mitsuma, Yuki Sunagawa, Kiyoshi Ishigure, Hiroyuki Yokoyama, Takanori Matsui, Hiroshi Nakayama, Kazuhiko Nakata, Akiharu Ishiyama, Takahiro Asada, Shinichi Umeda, Kazuhiro Ezaka, Norifumi Hattori, Hideki Takami, Daisuke Kobayashi, Chie Tanaka, Mitsuro Kanda, Suguru Yamada, Masahiko Koike, Michitaka Fujiwara, Tsutomu Fujii, Kenta Murotani, Yuichi Ando, Yasuhiro Kodera. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study). The Oncologist 2018; 23(8): 919 doi: 10.1634/theoncologist.2017-0640
|
| 65 |
Po-Jung Chen. Outcomes of upfront primary tumor resection in patients with synchronous RAS wild-type metastatic colorectal cancer. American Journal of Cancer Research 2024; 14(12): 5863 doi: 10.62347/DLWI1455
|
| 66 |
Nino Gullà, Roberto Cirocchi, Carlo Boselli, Iosief Abraha, Stefano Trastulli, Alessandro Montedori, Giuseppe Noya, Francesco Sciannameo, Roberto Cirocchi. Cochrane Database of Systematic Reviews. 2011; doi: 10.1002/14651858.CD008997
|
| 67 |
Gunnar Folprecht. Neoadjuvant chemotherapy for non-/resectable metastases. European Journal of Cancer 2011; 47: S52 doi: 10.1016/S0959-8049(11)70147-2
|
| 68 |
Yosuke Yoshida, Masayuki Kaneko, Mamoru Narukawa. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer. International Journal of Clinical Oncology 2020; 25(5): 851 doi: 10.1007/s10147-020-01619-8
|
| 69 |
Benoit You, Eric X. Chen. Anti‐EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. The Journal of Clinical Pharmacology 2012; 52(2): 128 doi: 10.1177/0091270010395940
|
| 70 |
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui. Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of Comparative Effectiveness Research 2023; 12(2) doi: 10.2217/cer-2022-0143
|
| 71 |
Feng Wen, Qiu Li. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World Journal of Gastroenterology 2016; 22(23): 5332-5341 doi: 10.3748/wjg.v22.i23.5332
|
| 72 |
Shukui Qin, Jin Li, Liwei Wang, Jianming Xu, Ying Cheng, Yuxian Bai, Wei Li, Nong Xu, Li-zhu Lin, Qiong Wu, Yunfeng Li, Jianwei Yang, Hongming Pan, Xuenong Ouyang, Wensheng Qiu, Kaichun Wu, Jianping Xiong, Guanghai Dai, Houjie Liang, Chunhong Hu, Jun Zhang, Min Tao, Qiang Yao, Junyuan Wang, Jiongjie Chen, S. Peter Eggleton, Tianshu Liu. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. Journal of Clinical Oncology 2018; 36(30): 3031 doi: 10.1200/JCO.2018.78.3183
|
| 73 |
René Adam, Emir Hoti, Luis César Bredt. Oncosurgical strategies for metastatic liver cancer. Cirugía Española (English Edition) 2011; 89(1): 10 doi: 10.1016/S2173-5077(11)70003-5
|
| 74 |
Junko Kato, Manabu Futamura, Masako Kanematsu, Siqin Gaowa, Ryutaro Mori, Toshiyuki Tanahashi, Nobuhisa Matsuhashi, Kazuhiro Yoshida. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. International Journal of Cancer 2016; 138(6): 1516 doi: 10.1002/ijc.29881
|
| 75 |
Sadayuki Kawai, Nozomi Takeshima, Yu Hayasaka, Akifumi Notsu, Mutsumi Yamazaki, Takanori Kawabata, Kentaro Yamazaki, Keita Mori, Hirofumi Yasui. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-07823-7
|
| 76 |
Gábor Lakatos, Claus-Henning Köhne, György Bodoky. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. Cancer and Metastasis Reviews 2020; 39(4): 1143 doi: 10.1007/s10555-020-09913-7
|
| 77 |
Sanne ten Hoorn, Dirkje W. Sommeijer, Faye Elliott, David Fisher, Tim R. de Back, Anne Trinh, Lianne Koens, Tim Maughan, Jenny Seligmann, Matthew T. Seymour, Phil Quirke, Richard Adams, Susan D. Richman, Cornelis J. A. Punt, Louis Vermeulen. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer 2021; 125(8): 1080 doi: 10.1038/s41416-021-01477-9
|
| 78 |
D. Gomez, A. De Rosa, A. Addison, A. Brooks, H.Z. Malik, I.C. Cameron. Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?. International Journal of Surgery 2013; 11(7): 507 doi: 10.1016/j.ijsu.2013.04.014
|
| 79 |
Toshihiro Shida, Yuji Endo, Tadashi Shiraishi, Takashi Yoshioka, Kaoru Suzuki, Yuka Kobayashi, Yuki Ono, Toshinori Ito, Tadao Inoue. Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis. YAKUGAKU ZASSHI 2018; 138(1): 83 doi: 10.1248/yakushi.17-00159
|
| 80 |
Huan Sun, Yonghong Li, Yana Su, Xinyu Wu, Xiaoqin Zhou, Jin Han, Jing Li. Efficacy and safety of anti‐EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild‐type metastatic colorectal cancer: A meta‐analysis. Journal of Evidence-Based Medicine 2019; 12(4): 300 doi: 10.1111/jebm.12360
|